{"filing":{"accession_number":"0001213900-26-075197","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ea0297034-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026075197/ea0297034-6k_radiopharm.htm"},"events":[{"id":16096,"run_id":14363,"accession_number":"0001213900-26-075197","anchor_item_number":"EX-99.1","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Radiopharm announces receipt of a A$5.9M R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material financial event — a significant cash inflow that the company explicitly states \"will provide important funding for continued development\" of its product pipeline. While not a traditional debt issuance, equity offering, or dividend, it is a material financial event that affects the registrant's liquidity and capital position, and does not fit the specific named financial categories (debt_issuance, dividend_distribution, etc.).","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14074,"accession_number":"0001213900-26-075197","item_number":"EX-99.1","item_title":"ea029703401ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Radiopharm announces receipt of a A$5.9M R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material financial event — a significant cash inflow that the company explicitly states \"will provide important funding for continued development\" of its product pipeline. While not a traditional debt issuance, equity offering, or dividend, it is a material financial event that affects the registrant's liquidity and capital position, and does not fit the specific named financial categories (debt_issuance, dividend_distribution, etc.).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:01:42.168078+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14074,"accession_number":"0001213900-26-075197","item_number":"EX-99.1","item_title":"ea029703401ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Radiopharm announces receipt of a A$5.9M R\u0026D tax refund from the Australian Government for the 2025 financial year. This is a material financial event — a significant cash inflow that the company explicitly states \"will provide important funding for continued development\" of its product pipeline. While not a traditional debt issuance, equity offering, or dividend, it is a material financial event that affects the registrant's liquidity and capital position, and does not fit the specific named financial categories (debt_issuance, dividend_distribution, etc.).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:01:42.168078+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-06"}]}